Lantern Pharma Inc
$ 3.88
-4.67%
12 Jun - close price
- Market Cap 49,504,400 USD
- Current Price $ 3.88
- High / Low $ 4.12 / 3.86
- Stock P/E N/A
- Book Value 0.31
- EPS -1.45
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.73 %
- ROE -1.57 %
- 52 Week High 5.74
- 52 Week Low 1.11
About
Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics, and machine learning. The company is headquartered in Dallas, Texas.
Analyst Target Price
$20.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-15 | 2026-03-30 | 2025-11-12 | 2025-08-13 | 2025-05-15 | 2025-03-27 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-18 | 2023-11-08 | 2023-08-09 |
| Reported EPS | -0.3 | -0.36 | -0.39 | -0.4 | -0.42 | -0.54 | -0.42 | -0.46 | -0.51 | -0.39 | -0.29 | -0.44 |
| Estimated EPS | -0.36 | -0.46 | -0.44 | -0.53 | -0.43 | -0.51 | -0.56 | -0.55 | -0.43 | -0.4 | -0.45 | -0.43 |
| Surprise | 0.06 | 0.1 | 0.05 | 0.13 | 0.01 | -0.03 | 0.14 | 0.09 | -0.08 | 0.01 | 0.16 | -0.01 |
| Surprise Percentage | 16.6667% | 21.7391% | 11.3636% | 24.5283% | 2.3256% | -5.8824% | 25% | 16.3636% | -18.6047% | 2.5% | 35.5556% | -2.3256% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LTRN
2026-06-12 20:40:14
Lantern Pharma (NASDAQ: LTRN) has filed an S-1 registration statement for the resale of 2.24 million shares of common stock tied to warrants from a May 2026 financing. The company will not receive proceeds from these resales, but may acquire up to $5.1 million if all warrants are exercised for cash. LTRN reported $6.3 million in cash as of March 31, 2026, which is expected to fund operations only until mid-Q1 2027, leading auditors to express substantial doubt about its ability to continue without significant additional funding.
2026-06-12 06:40:14
Lantern Pharma Inc. (LTRN) saw its stock surge by 18% in pre-market trading after the FDA cleared its Investigational New Drug application for STAR-001, allowing the company to begin a Phase 1 pediatric clinical trial for central nervous system cancers. STAR-001 was discovered using Lantern's proprietary RADR AI platform and will be evaluated alone and in combination with Spironolactone. This news follows earlier FDA Orphan Drug Designation for another Lantern Pharma drug, LP-284, for soft tissue sarcomas.
2026-06-03 03:09:44
Lantern Pharma reported clinical data from its Phase 2 HARMONIC™ trial for LP-300 in EGFR Exon 21 L858R-mutant NSCLC, showing that progression-free survival benefit for LP-300 deepens with treatment duration, especially in the L858R subgroup. Patients treated through six cycles achieved an 8.9-month median PFS, with a clean safety profile supporting extended treatment. The company is using this data for partnering and clinical discussions at ASCO 2026, targeting the unmet need for L858R patients.
2026-06-02 15:40:04
Lantern Pharma reported clinical data from its HARMONIC™ trial, demonstrating that the progression-free survival (PFS) benefit of LP-300 deepens with treatment duration, particularly in EGFR Exon 21 L858R-mutant non-small cell lung cancer patients. Patients treated for up to six cycles achieved an 8.9-month median PFS, and the drug exhibited a clean safety profile, enabling extended treatment. The company is using this updated data for partnering and clinical discussions during ASCO 2026.
2026-06-02 14:40:35
Lantern Pharma Inc. (NASDAQ:LTRN) saw its shares rise after reporting extended survival data from its Phase 2 lung cancer trial. Patients treated with LP-300 plus chemotherapy achieved a median progression-free survival of 8.9 months, with over 70% experiencing tumor reduction. The company also highlighted favorable comparisons to FDA-approved therapies regarding toxicity and has received FDA clearance to extend LP-300 dosing.
2026-06-02 12:10:29
Lantern Pharma announced new data from its HARMONIC™ trial, indicating that LP-300, in combination with chemotherapy, shows a deepening progression-free survival (PFS) benefit with longer treatment duration in EGFR Exon 21 L858R lung cancer patients. Patients treated for up to six cycles achieved an 8.9-month median PFS, with durable responses and a favorable safety profile compared to existing treatments. The company is using this data for partnering discussions during ASCO 2026 and plans to extend LP-300 dosing to eight cycles, focusing on the L858R subgroup.
